<DOC>
	<DOCNO>NCT00886574</DOCNO>
	<brief_summary>This multi-center , randomize control study aim evaluate efficacy Cilostazol versus Aspirin primary prevention atherosclerotic event Korean type 2 Diabetes Mellitus ( DM ) patient .</brief_summary>
	<brief_title>Cilostazol Versus Aspirin Primary Prevention Atherosclerotic Events</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Type 2 diabetes mellitus high risk macrovascular complication ; high risk one follow : Hypertension ( â‰§ 140/90 antihypertensive therapy ) Hypercholesterolemia ( LDLC &gt; 130 mg/dL antihyperlipidemic therapy ) TG &gt; 200 mg/dL Non proliferative retinopathy macular edema Microalbuminuria macroalbuminuria Smoker 2 . Patients anti PLT drug history 3 . Patients agree research 1 . Type 1 diabetes mellitus 2 . Macrovascular complication history 3 . Uncontrolled hypertension , unstable angina history 4 . Congestive heart failure 5 . Bleeding tendency 6 . Chronic liver disease ( ALT &gt; 100 AST &gt; 100 ) Chronic renal disease creatinine &gt; 3.0 mg/dl ) 7 . Anemia ( hemoglobin &lt; 10 mg/dl ) thrombocytopenia ( platelet count le 100,000/mm3 ) 8 . Pregnant lactation woman 9 . Plan revascularized 4 week 10 . Plan go surgery invasive intervention 4 week 11 . Plan need admission acute cardiovascular disease 4 week 12 . Contraindication medication 13 . Other antiPLT drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Cilostazol versus Aspirin</keyword>
	<keyword>Anti-PLT drug</keyword>
	<keyword>Primary Prevention Atherosclerotic Events</keyword>
	<keyword>Type 2 DM</keyword>
	<keyword>Intima medium thickness ( IMT )</keyword>
</DOC>